Small Business Resources, Business Advice and Forms from AllBusiness.com

Schering Entered into Illegal Settlements with Generic Drug Firms, FTC Rules.

By Lewis Krauskopf, The Record, Hackensack, N.J. Knight Ridder/Tribune Business News

Dec. 19--Schering-Plough Corp. entered into illegal settlements with generic drug companies that delayed lower-priced versions of its widely used potassium drug, the Federal Trade Commission said Thursday.

The commission's ruling reversed a decision last year by an administrative law judge that had cleared Schering-Plough of the anti-competitive charges. The Kenilworth-based drug maker said Thursday it "strongly disagreed" with the decision and vowed to appeal.

<

In addition, make sure to read these premium articles also available with your free trial:

T T T
art_print Printart_email Email 16x16-digg-guy  Digg It delicious-small  del.icio.us

Related Resources

Free AllBusiness Articles

  • Pharmaceutical Marketing Practices: Pharmaceutical Companies Facing Competition from Generic Drug Manufacturers May Face Increased Scrutiny for Anticompetitive Marketing Practices-In re Warfarin Sodium...
    • Pharmaceutical Marketing Practices: Pharmaceutical Companies Facing Competition from Generic Drug Manufacturers May Face Increased Scrutiny for Anticompetitive Marketing Practices-In re Warfarin Sodium Antitrust Litig.1-The United States Court of Appeals for the Third Circuit rejected challenges to a $44.5 million settlement against DuPont Pharmaceuticals Co. ("DuPont"). The settlement ended a class-action ......
  • Wave of lawsuits filed over cholesterol drugs
    • A wave of lawsuits filed in the wake of a recent study accuses Merck and Schering-Plough of grossly overpricing their Vytorin and Zetia cholesterol medications, and covering up findings that the drugs were no more effective than lower-priced generics. Marketed jointly by Merck and Schering-Plough, Vytorin is a composite of ......
  • Court blocks FDA regulation, this time on generic drugs
    • Another FDA regulation was struck down by the U.S. district court in Washington, this time covering the approval process for generic drugs. Under the law, the first manufacturer to seek approval of a generic drug from the FDA gets a 180-day period of exclusive rights to the market. If the......
  • Stradling Lawyer Wins for Generics; Appeal Pending
    • HEADNOTE Doctors' Blood Boils Over CalOptima HMO; Blue Shield Honors Hospitals for Cardiac Care HEALTHCARE A patent fight led by an Orange County law firm could add up to a windfall for a generic drug maker. U.S. District Judge Robert Timlin last month granted a summary judgment in favor of ......
  • Calming anxiety on prices. (Names in the News).
    • BRISTOL-MYERS SQUIBB HAS AGREED to settle a lawsuit alleging improper efforts to monopolize the market for BuSpar, its popular anti-anxiety drug. The suit, filed by the consumer coalition Prescription Access Litigation (PAL) project, charged that the company illegally manipulated patent law to keep a generic, cheaper version of BuSpar off ......
  • Cephalon files narcolepsy patent infringement lawsuit.
    • Cephalon, Inc. (West Chester, PA) has filed a lawsuit in United States District Court in New Jersey against four generic drug companies for infringement of Cephalon's United States Patent RE37516. The '516 patent covers the pharmaceutical compositions of the form of modafinil contained in PROVIGIL Tablets (C-IV) and does not ......
  • Bill would aid Lilly's generic competition
    • The cost of prescription drugs - and what several members of Congress are trying to do about it - has added fuel to a debate about generic medications that strikes close to home for Indianapolis-based Eli Lilly and Co. Having already lost its patent protection on its blockbuster drug Prozac ......
Related Topics
Tools

Sponsored Links

Site Map | Contact Us | FAQs | About Us | Media Kit | Reprints | RSS Directory | Sign Up for Free Newsletters | Disclosure Policy

Copyright © 1999 - 2008 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.

Get In-Depth Company Information from Hoover's | Buy a D&B Credit Report | What is in Your Company's D&B Credit Report? | Article Archives
Online Business Database | Online Business Information | Email Marketing Lists | Sales and Marketing Solutions | Business Mailing Lists
Information and opinions on AllBusiness.com solely represent the thoughts and opinions of the authors and are not endorsed by, or reflect the beliefs of,
AllBusiness.com, its parent company D&B, and its affiliates.